Physician profile
Michelle C Hure
NPI 1760656169
$4,878.95
in general payments reported to CMS, 2019-2025
11 companies · $3,523 in 2025
The $3,523 reported for 2025 was more than what 94% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2021: $21.14 · 2022: $93.71 · 2023: $410 · 2024: $296 · 2025: $3,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $1,402 · Travel and Lodging: $27.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $1,401.68 |
| Travel and Lodging | $27.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,300.57 | 2023-2025 | Winlevi |
| Incyte Corporation | $401.91 | 2024-2025 | Opzelura |
| Merz North America, INC. | $235.28 | 2019 | |
| Galderma Laboratories, L.P. | $213.98 | 2019-2025 | Epsolay, Twyneo |
| Prugen, INC. Pharmaceuticals | $136.61 | 2019 | |
| Celgene Corporation | $123.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $121.38 | 2023 | Sotyktu |
| Leo Pharma INC. | $113.38 | 2023 | Adbry |
| Regeneron Healthcare Solutions, INC. | $94.63 | 2019-2025 | Dupixent |
| Ucb, INC. | $93.71 | 2022 | |
| Revance Therapeutics, INC. | $44.33 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Hure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.